|
1
|
Saito Y, Hibino S and Saito H: Alterations
of epigenetics and microRNA in hepatocellular carcinoma. Hepatol
Res. 44:31–42. 2014. View Article : Google Scholar
|
|
2
|
Liu J, Liu X, Cui F, Chen G, Guan Y and He
J: The efficacy of the inhalation of an aerosolized Group A
streptococcal preparation in the treatment of lung cancer. Chin J
Cancer Res. 24:346–352. 2012. View Article : Google Scholar
|
|
3
|
Skinner HD and Komaki R: Proton
radiotherapy in the treatment of lung cancer. Transl Cancer Res.
1:264–270. 2012.
|
|
4
|
Quintavalle C and Condorelli G: Dulanermin
in cancer therapy: Still much to do. Transl Lung Cancer Res.
1:158–159. 2012.PubMed/NCBI
|
|
5
|
Yamashita S, Yamamoto H, Mimori K, Nishida
N, Takahashi H, Haraguchi N, Tanaka F, Shibata K, Sekimoto M, Ishii
H, et al: MicroRNA-372 is associated with poor prognosis in
colorectal cancer. Oncology. 82:205–212. 2012.PubMed/NCBI
|
|
6
|
Weiland M, Gao XH, Zhou L and Mi QS: Small
RNAs have a large impact: Circulating microRNAs as biomarkers for
human diseases. RNA Biol. 9:850–859. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tjensvoll K, Svendsen KN, Reuben JM,
Oltedal S, Gilje B, Smaaland R and Nordgård O: miRNA expression
profiling for identification of potential breast cancer biomarkers.
Biomarkers. 17:463–470. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Papaconstantinou I, Karakatsanis A,
Gazouli M, Polymeneas G and Voros D: The role of microRNAs in liver
cancer. Eur J Gastroenterol Hepatol. 24:223–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
10
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu QY, Jiang H, Su J and Jia YQ: MicroRNAs
as biomarkers for hepatocellular carcinoma: A diagnostic
meta-analysis. Clin Lab. 59:1113–1120. 2013.PubMed/NCBI
|
|
12
|
Pass HI: Biomarkers and prognostic factors
for mesothelioma. Ann Cardiothorac Surg. 1:449–456. 2012.
|
|
13
|
Coppola V, Musumeci M, Patrizii M,
Cannistraci A, Addario A, Maugeri-Saccà M, Biffoni M,
Francescangeli F, Cordenonsi M, Piccolo S, et al: BTG2 loss and
miR-21 upregulation contribute to prostate cell transformation by
inducing luminal markers expression and epithelial-mesenchymal
transition. Oncogene. 32:1843–1853. 2013. View Article : Google Scholar
|
|
14
|
Niu J, Shi Y, Tan G, Yang CH, Fan M,
Pfeffer LM and Wu ZH: DNA damage induces NF-κB-dependent
microRNA-21 up-regulation and promotes breast cancer cell invasion.
J Biol Chem. 287:21783–21795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY and
Yan M: microRNA-21 promotes tumor proliferation and invasion in
gastric cancer by targeting PTEN. Oncol Rep. 27:1019–1026.
2012.PubMed/NCBI
|
|
16
|
Shibuya H, Iinuma H, Shimada R, Horiuchi A
and Watanabe T: Clinicopathological and prognostic value of
microRNA-21 and microRNA-155 in colorectal cancer. Oncology.
79:313–320. 2010. View Article : Google Scholar
|
|
17
|
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K
and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN
and promotes growth and invasion in non-small cell lung cancer
(NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao J, Zhang Q, Xu J, Guo L and Li X:
Clinical significance of serum miR-21 in breast cancer compared
with CA153 and CEA. Chin J Cancer Res. 25:743–748. 2013.
|
|
19
|
Petrović N, Mandušić V, Stanojević B,
Lukić S, Todorović L, Roganović J and Dimitrijević B: The
difference in miR-21 expression levels between invasive and
non-invasive breast cancers emphasizes its role in breast cancer
invasion. Med Oncol. 31:8672014. View Article : Google Scholar
|
|
20
|
Li T, Leong MH, Harms B, Kennedy G and
Chen L: MicroRNA-21 as a potential colon and rectal cancer
biomarker. World J Gastroenterol. 19:5615–5621. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Zhu H, Yang X, Ge Y, Zhang C, Qin
Q, Lu J, Zhan L, Cheng H and Sun X: MicroRNA-21 is a novel
promising target in cancer radiation therapy. Tumour Biol.
35:3975–3979. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li L, Zhou L, Li Y, Lin S and Tomuleasa C:
MicroRNA-21 stimulates gastric cancer growth and invasion by
inhibiting the tumor suppressor effects of programmed cell death
protein 4 and phosphatase and tensin homolog. J BUON. 19:228–236.
2014.PubMed/NCBI
|
|
23
|
Liu M, Wu H, Liu T, Li Y, Wang F, Wan H,
Li X and Tang H: Regulation of the cell cycle gene, BTG2, by miR-21
in human laryngeal carcinoma. Cell Res. 19:828–837. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lim IK: TIS21 (/BTG2/PC3) as a link
between ageing and cancer: Cell cycle regulator and endogenous cell
death molecule. J Cancer Res Clin Oncol. 132:417–426. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Melamed J, Kernizan S and Walden PD:
Expression of B-cell translocation gene 2 protein in normal human
tissues. Tissue Cell. 34:28–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei S, Hao C, Li X, Zhao H, Chen J and
Zhou Q: Effects of BTG2 on proliferation inhibition and
anti-invasion in human lung cancer cells. Tumour Biol.
33:1223–1230. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wagener N, Bulkescher J, Macher-Goeppinger
S, Karapanagiotou-Schenkel I, Hatiboglu G, Abdel-Rahim M,
Abol-Enein H, Ghoneim MA, Bastian PJ, Müller SC, et al: Endogenous
BTG2 expression stimulates migration of bladder cancer cells and
correlates with poor clinical prognosis for bladder cancer
patients. Br J Cancer. 108:973–982. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choi KS, Kim JY, Lim SK, Choi YW, Kim YH,
Kang SY, Park TJ and Lim IK: TIS21(/BTG2/PC3) accelerates the
repair of DNA double strand breaks by enhancing Mre11 methylation
and blocking damage signal transfer to the Chk2(T68)-p53(S20)
pathway. DNA Repair (Amst). 11:965–975. 2012. View Article : Google Scholar
|
|
29
|
Zhang YJ, Wei L, Liu M, Li J, Zheng YQ,
Gao Y and Li XR: BTG2 inhibits the proliferation, invasion, and
apoptosis of MDA-MB-231 triple-negative breast cancer cells. Tumour
Biol. 34:1605–1613. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Z, Chen C, Wang G, Yang Z, San J,
Zheng J, Li Q, Luo X, Hu Q, Li Z and Wang D: Aberrant expression of
the p53-inducible antiproliferative gene BTG2 in hepatocellular
carcinoma is associated with overexpression of the cell
cycle-related proteins. Cell Biochem Biophys. 61:83–91. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang ZM, Wang G, Yang ZX, Shan JL, Chen
C, Jin F, Xu W, Li Q, Luo XZ, Wang D and Li ZP: The expression of
B-cell translocation gene 2 in diethylnitrosamine-induced primary
hepatocellular carcinoma rat model. Zhonghua Gan Zang Bing Za Zhi.
17:107–111. 2009.In Chinese. PubMed/NCBI
|
|
32
|
Yang CH, Yue J, Pfeffer SR, Handorf CR and
Pfeffer LM: MicroRNA miR-21 regulates the metastatic behavior of
B16 melanoma cells. J Biol Chem. 286:39172–39178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takahashi F, Chiba N, Tajima K, Hayashida
T, Shimada T, Takahashi M, Moriyama H, Brachtel E, Edelman EJ,
Ramaswamy S and Maheswaran S: Breast tumor progression induced by
loss of BTG2 expression is inhibited by targeted therapy with the
ErbB/HER inhibitor lapatinib. Oncogene. 30:3084–3095. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang L, Huang H, Wu K, Wang M and Wu B:
Impact of BTG2 expression on proliferation and invasion of gastric
cancer cells in vitro. Mol Biol Rep. 37:2579–2586. 2010. View Article : Google Scholar
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
36
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nair VS, Maeda LS and Ioannidis JP:
Clinical outcome prediction by microRNAs in human cancer: A
systematic review. J Natl Cancer Inst. 104:528–540. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ross SA and Davis CD: MicroRNA, nutrition,
and cancer prevention. Adv Nutr. 2:472–485. 2011. View Article : Google Scholar :
|
|
40
|
Li Q, Wang G, Shan JL, Yang ZX, Wang HZ,
Feng J, Zhen JJ, Chen C, Zhang ZM, Xu W, et al: MicroRNA-224 is
upregulated in HepG2 cells and involved in cellular migration and
invasion. J Gastroenterol Hepatol. 25:164–171. 2010. View Article : Google Scholar
|
|
41
|
Li Q, Ding C, Chen C, Zhang Z, Xiao H, Xie
F, Lei L, Chen Y, Mao B, Jiang M, et al: miR-224 promotion of cell
migration and invasion by targeting Homeobox D 10 gene in human
hepatocellular carcinoma. J Gastroenterol Hepatol. 29:835–842.
2014. View Article : Google Scholar
|
|
42
|
Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21
targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol
Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ryu MS, Lee MS, Hong JW, Hahn TR, Moon E
and Lim IK: TIS21/BTG2/PC3 is expressed through PKC-delta pathway
and inhibits binding of cyclin B1-Cdc2 and its activity,
independent of p53 expression. Exp Cell Res. 299:159–170. 2004.
View Article : Google Scholar : PubMed/NCBI
|
